User:Mr. Ibrahem/Patisiran
 | |
| Clinical data | |
|---|---|
| Trade names | Onpattro |
| Other names | ALN-18328 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous |
| Drug class | Small interfering RNA (siRNA)[1] |
| Legal status | |
| Legal status |
|
| Chemical and physical data | |
| Formula | C412H520N148O290P40 |
| Molar mass | 13424.388 g·mol−1 |
Patisiran, sold under the brand name Onpattro, is a medication used to treat polyneuropathy in people with hereditary transthyretin-mediated amyloidosis.[1] It is given by gradual injection into a vein.[2]
Common side effects include upper respiratory infection, shortness of breath, muscle spasms, joint pain, redness, and dizziness.[1] Other side effects may include vitamin A deficiency.[1] Safety in pregnancy is unclear; though evidence shows harm in other animals.[1] It is a small piece of RNA that blocks the production of abnormal transthyretin.[3]
Patisiran was approved for medical use in Europe and the United States in 2018.[3][1] In the United Kingdom a single vial of 10 mg costs the NHS about £7,700 as of 2021.[2] This amount in the United States costs about 10,000 USD.[4]
References[edit]
- ^ a b c d e f g h "Patisiran Monograph for Professionals". Drugs.com. Archived from the original on 26 January 2021. Retrieved 26 October 2021.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1109. ISBN 978-0857114105.
- ^ a b "Onpattro". Archived from the original on 8 November 2020. Retrieved 26 October 2021.
- ^ "Onpattro Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 24 June 2021. Retrieved 26 October 2021.